Journal of Thrombosis and Thrombolysis

, Volume 29, Issue 4, pp 503–511

Severe bleeding secondary to misuse of fondaparinux: a case report

  • Hubert Nielly
  • Aurore Bousquet
  • Patrick Le Garlantezec
  • Eric Perrier
  • Xavier Bohand


Venous thromboembolism (VTE) remains a great challenge because of its frequency and of its potential severity. However, VTE treatment can also lead to iatrogenic complications. We report a case of thigh haematoma by a 83-year-old woman under fondaparinux for a solear thrombosis. Then we discuss the indications of Unfractionated Heparin (UFH), Low-Molecular-Weight Heparins (LMWH) and Fondaparinux, which are the three classes of rapidly acting anticoagulant treatments nowadays available. As their efficacy is comparable, the choice between these classes relies on the risk of adverse effects, which depends on some patient’s characteristics. LMWH and fondaparinux are contra-indicated by the patients with a renal clearance under 30 ml/min. Only UFH are authorised during the whole pregnancy even though LMWH are more and more used. Fondaparinux has proven its safety by patients over 100 kg. UFH requires a daily biological management whereas it is optional for LMWH and fondaparinux, as long as their contra-indications are taken into account. No Heparin-induced-thrombocytopenia Syndrome (HIT-Sd) has been proven yet under fondaparinux so that platelets management seems not necessary, contrary to UFH and LMWH which require a twice-weekly platelets count. The accuracy of the therapeutic indication should result in the best benefit/risk assessment.


Fondaparinux Veinous thromboembolism Unfractionated heparins 


  1. 1.
    Bénard E, Lafuma A, Ravaud P (2005) Epidémiologie de la maladie thromboembolique veineuse. Presse Med 34:415–419CrossRefPubMedGoogle Scholar
  2. 2.
    Dalen JE (2002) Pulmonary embolism: what have we learned since Virchow? Natural history, pathophysiology, and diagnosis. Chest 122:1440–1456CrossRefPubMedGoogle Scholar
  3. 3.
    Grand’Maison A, Charest AF, Geerts WH (2005) Anticoagulant use in patients with chronic renal impairment. Am J Cardiovasc Drugs 5(5):291–305CrossRefPubMedGoogle Scholar
  4. 4.
    Spyropoulos AC, Merli G (2006) Management of venous thromboembolism in the elderly. Drugs Aging 23(8):651–671CrossRefPubMedGoogle Scholar
  5. 5.
    Boneu B, Necciari J, Cariou R et al (1995) Pharmacokinetics and tolerance of the natural pentasaccharide (SR90107/Org31540) with high affinity to antithrombin III in man. Thromb Haemost 74:1468–1473PubMedGoogle Scholar
  6. 6.
    Dolovich LR, Gisberg JS, Douketis JD et al (2000) A meta-analysis comparing low-molecular-weight heparins with unfractionated heparin in the treatment of venous thromboembolism. Arch Intern Med 160:181–188CrossRefPubMedGoogle Scholar
  7. 7.
    The Rembrandt Investigators (2000) Treatment of proximal deep vein thrombosis with a novel synthetic compound (SR90107A/ORG31540) with pure anti-factor Xa Activity. Circulation 102(22):2726–2731Google Scholar
  8. 8.
    The Matisse Investigators (2003) Subcutaneous fondaparinux versus intravenous unfractionated heparin in the initial treatment of pulmonary embolism. N Eng J Med 349:1695–1702CrossRefGoogle Scholar
  9. 9.
    Siguret V, Pautas E, Gouin I (2004) Low molecular weight heparin treatment in elderly subjects with or without renal insufficiency: new insights between June 2002 and March 2004. Curr Opin Pulm Med 10:366–370CrossRefPubMedGoogle Scholar
  10. 10.
    Nilsson CU, Engström M (2007) Monitoring fondaparinux with the Sonoclot. Blood Coagul Fibrinolysis 18(7):619–622CrossRefPubMedGoogle Scholar
  11. 11.
    Bauer KA, Hawkins DW, Peters PC et al (2002) Fondaparinux, a synthetic pentasaccharide: the first in a new class of antithrombotic agents—the selective factor Xa inhibitors. Cardiovasc Drug Rev 20:37–52PubMedGoogle Scholar
  12. 12.
    Grateau G, Chauvenet L, Oudard S et al (1997) Severe low molecular weight heparin-related bleedings. Two cases. Rev Med Intern 18(5):411–415CrossRefGoogle Scholar
  13. 13.
    Schulman S, Beyth RJ, Kearon C, Levine MN (2008) American college of chest physicians. Hemorrhagic complications of anticoagulant and thrombolytic treatment: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 133(6 Suppl):257S–298SCrossRefPubMedGoogle Scholar
  14. 14.
    Falgá C, Capdevila JA, Soler S et al (2007) RIETE Investigators. Clinical outcome of patients with venous thromboembolism and renal insufficiency. Findings from the RIETE registry. Thromb Haemost 98(4):771–776PubMedGoogle Scholar
  15. 15.
    The Matisse investigators (2004) Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis. Ann Intern Med 140:867–873Google Scholar
  16. 16.
    Cheng JW (2002) Fondaparinux: a new antithrombotic agent. Clin Ther 24(11):1757–1769CrossRefPubMedGoogle Scholar
  17. 17.
    Shorr AF (2007) The pharmacoeconomics of deep vein thrombosis treatment. Am J Med 120(10 Suppl 2):S35–S41CrossRefPubMedGoogle Scholar
  18. 18.
    ARIXTRA [package insert]. Glaxo-SmithKline, Research Triangle Park, NC (2005)Google Scholar
  19. 19.
    Joubaud P (2004) Variations en fonction de l’âge et du sexe de la clairance de la créatinine estimée selon Cockcroft et Gault dans une population sélectionnée d’adultes non hospitalisés. Ann Biol Clin (Paris) 62(5):547–554Google Scholar
  20. 20.
    Agence française de sécurité sanitaire des produits de santé. Lettre destinée aux professionnels de santé. Informations importantes concernant la sécurité d’emploi du fondaparinux: Rappel du bon usage [on line]. Available from http://www.afssaps.santé.fr (18 juin 2007)
  21. 21.
    Lisman T et al (2003) Recombinant factor VIIa reverses the in vitro and ex vivo anticoagulant and profibrinolytic effects of fondaparinux. J Thromb Haemost 1(11):2368–2373CrossRefPubMedGoogle Scholar
  22. 22.
    Bijsterveld NR et al (2004) Recombinant factor VIIa reverses the anticoagulant effect of the long-acting pentasaccharide idraparinux in healthy volunteers. Br J Haematol 124:653–658CrossRefPubMedGoogle Scholar
  23. 23.
    Hirsh J, Raschke R (2004) Heparin and low-molecular-weight heparin. The seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest 126:188S–203SCrossRefPubMedGoogle Scholar
  24. 24.
    Warkentin TE, Greinacher A (2004) Heparin-induced thrombocytopenia: recognition, treatment, and prevention: the seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest 126(3 Suppl):311S–337SCrossRefPubMedGoogle Scholar
  25. 25.
    Kelton JG, Warkentin TE (2008) Heparin-induced thrombopenia: a historical perspective. Blood 112(7):2607–2616CrossRefPubMedGoogle Scholar
  26. 26.
    Martel N, Lee J, Wells PS (2005) Risk for heparin-induced thrombocytopenia with unfractionated and low-molecular-weight heparin thromboprophylaxis: a meta-analysis. Blood 106(8):2710–2715CrossRefPubMedGoogle Scholar
  27. 27.
    Prandoni P, Siragusa S, Girolami B, Fabris F, BELZONI Investigators Group (2005) The incidence of heparin-induced thrombocytopenia in medical patients treated with low-molecular-weight heparin: a prospective cohort study. Blood 106(9):3049–3054CrossRefPubMedGoogle Scholar
  28. 28.
    Girolami B, Prandoni P, Stefani PM et al (2003) The incidence of heparin-induced thrombocytopenia in hospitalized medical patients treated with subcutaneous unfractionated heparin: a prospective cohort study. Blood 101:2955–2959CrossRefPubMedGoogle Scholar
  29. 29.
    Maccarana M, Lindahl U (1993) Mode of interaction between platelet factor 4 and heparin. Glycobiology 3:271–277CrossRefPubMedGoogle Scholar
  30. 30.
    Warkentin TE, Cook RJ, Marder VJ et al (2005) Anti-platelet factor 4/heparin antibodies in orthopedic surgery patients receiving antithrombotic prophylaxis with fondaparinux or enoxaparin. Blood 106(12):3791–3796CrossRefPubMedGoogle Scholar
  31. 31.
    Warkentin TE, Maurer BT, Aster RH (2007) Heparin-induced thrombopenia associated with fondaparinux. N Engl J Med 356(25):2653–2655 discussion 2653–2655CrossRefPubMedGoogle Scholar
  32. 32.
    Harenberg J, Jorg I, Fenyvesi T (2004) Treatment of heparin-induced thrombocytopenia with fondaparinux. Haematologica 89:1017–1018PubMedGoogle Scholar
  33. 33.
    Davidson BL, Buller HR, Decousus H et al (August 5, 2005) Outcomes in obese patients of pulmonary embolism and deep vein thrombosis treatment with fondaparinux or low-molecular-weight heparins: the MATISSE trials. In: Poster presented at the Annual Meeting of the International Society on Thrombosis and Haemostasis, Sydney, AustraliaGoogle Scholar
  34. 34.
    Gould MK, Dembitzer AD, Sanders GD, Garber AM (1999) Low-molecular-weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis. A cost-effectiveness analysis. Ann Intern Med 130(10):789–799PubMedGoogle Scholar
  35. 35.
    Hyers TM (2003) Management of venous thromboembolism: past, present and future. Arch Intern Med 163(7):759–768CrossRefPubMedGoogle Scholar
  36. 36.
    The Matisse investigators (2004) Fondaparinux or enoxaparin for the initial treatmant of symptomatic deep vein thrombosis. Ann Intern Med 140:867–873Google Scholar
  37. 37.
    Warkentin TE, Greinacher A, Koster A, Lincoff AM (2008) American College of chest physicians. Treatment and prévention of heparin-induced thrombocytopenia: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 133(6 Suppl):340S–380SCrossRefPubMedGoogle Scholar
  38. 38.
    Dinwoodey DL, Ansell JE (2006) Heparins, low-molecular-weight heparins, and pentasaccharides. Clin Geriatr Med 22:1–15CrossRefPubMedGoogle Scholar
  39. 39.
    Duchaussoy P et al (1999) Identification of a hexasaccharide sequence able to inhibit thrombin and suitable for ‘polymerisation’. Carbohydr Res 317(1–4):63–84CrossRefPubMedGoogle Scholar
  40. 40.
    Hirsh J, Ofosu F, Buchanan M (1985) Rationale behind the development of low molecular weight heparin derivatives. Semin Thromb Hemost 11(1):13–16CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2009

Authors and Affiliations

  • Hubert Nielly
    • 1
  • Aurore Bousquet
    • 2
  • Patrick Le Garlantezec
    • 2
  • Eric Perrier
    • 1
  • Xavier Bohand
    • 2
  1. 1.Service de Cardiologie Hôpital d’Instruction des Armées PERCYClamartFrance
  2. 2.Service de Pharmacie Hospitalière Hôpital d’Instruction des Armées PERCYClamartFrance

Personalised recommendations